TMB

NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management

Retrieved on: 
Mardi, mai 28, 2024
Radiology, Pharmaceutical, Medical Supplies, Oncology, Health, Health Technology, Genetics, Clinical Trials, NGS, NEO, Patient, Prognosis, DNA, Bone marrow, Leukemia, Clinical trial, Diagnosis, FDA, TMB, Multiple myeloma, NSCLC, Lung, Cancer, NCCN, National Comprehensive Cancer Network, MSI, ASCO, Gene, RNA, COMPASS, Society, Lymphoma, Vaccine

DNA & RNA Lung is a 50-gene NGS panel enriched with MSI and TMB analysis to facilitate precise therapy selection and clinical trial matching.

Key Points: 
  • DNA & RNA Lung is a 50-gene NGS panel enriched with MSI and TMB analysis to facilitate precise therapy selection and clinical trial matching.
  • InvisionFirst® Lung is a liquid biopsy assay that detects 37 genes crucial to NSCLC treatment.
  • NeoGenomics will also feature COMPASS, a suite of single-order sample-to-diagnosis services for hematological malignancies.
  • COMPASS provides an all-in-one assessment with actionable diagnostic and prognostic information unique to the patient.

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Retrieved on: 
Lundi, avril 22, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Education, National Cancer Center, MET, D.C, Lung cancer, Woman, PMID, Progression-free survival, Harmonic, Machine learning, AME Publishing Company, ClinicalTrials.gov, Collection, Artificial intelligence, IPhone, Adenocarcinoma, ROS1, Disease, Incidence, Patient, Pemetrexed, TMB, SOC, Neoplasm, Lung, ALK, EGFR, NSCLC, Carboplatin, Overalls, Gene, TK, Pharmaceutical industry

Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).

Key Points: 
  • Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).
  • LCINS are histologically, mutationally, and epidemiologically distinct from smoking-related lung cancers and occur almost exclusively as adenocarcinomas and most commonly in women and individuals of Asian ancestry.
  • Dr. Goto will now lead the trial in Japan, where the incidence of non-small cell lung cancer (NSCLC) in never-smokers is double or more than that of the United States.
  • In addition, LP-300 has been administered in multiple clinical trials to more than 1,000 people and has been generally well tolerated.

CAP Publishes Guideline for PD-L1 Testing of Patients with Lung Cancer

Retrieved on: 
Mardi, avril 16, 2024
University, Education, Health, General Health, Oncology, Other Science, Research, Science, Other Education, Clinical Trials, Continuing, Patient, Lung cancer, Programmed cell death, Laboratory, Survival, Immunotherapy, Medical laboratory, Pathology, IHC, PD-1, Guideline, Apoptosis, PD-L1, International Association, TMB, AMP, College, CAP, Biomarker, Immune system, Antibody, Running, NSCLC, Capitol, PPS

“Many lung cancer patients may benefit from therapies that can harness the immune system, including anti-PD-1 or PD-L1 therapies.

Key Points: 
  • “Many lung cancer patients may benefit from therapies that can harness the immune system, including anti-PD-1 or PD-L1 therapies.
  • “This guideline is intended to provide an overview of the clinical rationale for the use of PD-L1 and tumor mutational burden (TMB) testing for patients with non-small lung cancer.
  • With six recommendations, the guideline provides data and details regarding the efficacy and utility of PD-L1 testing of patients with lung cancer.
  • Current tools, resources, and information for the PD-L1 Testing of Patients with Lung Cancer Guideline can be found on the guideline webpage on cap.org.

TMB Appoints Top Media Executive, Marty Moe, President

Retrieved on: 
Jeudi, avril 25, 2024
Pet, News, Treasury, Jukin Media, Digest, Vox Media, SB Nation, SVP, Editorial, TMB, The Family Handyman, AOL, Taste, Growth

NEW YORK, April 25, 2024 /PRNewswire/ -- TMB, the community-driven entertainment company, is excited to announce that Marty Moe has been appointed President. Moe will oversee TMB's web, social and streaming businesses. He will be responsible for driving growth and transformation among TMB's portfolio of brands, including Family Handyman, FailArmy, The Pet Collective, Taste of Home and Reader's Digest. Moe has a diverse media background and holds an impressive record of driving powerful revenue growth and progressive business strategies across platforms.

Key Points: 
  • Moe, previously president at Vox Media, will join Trusted Media Brands effective May 6.
  • NEW YORK, April 25, 2024 /PRNewswire/ -- TMB , the community-driven entertainment company, is excited to announce that Marty Moe has been appointed President.
  • "I am thrilled to welcome Marty Moe to the TMB leadership team," said CEO Bonnie Kintzer.
  • Moe joins TMB after 13 years at Vox Media where he most recently served as president of Vox Media Studios.

Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)

Retrieved on: 
Mardi, avril 16, 2024
Melanoma Research, Cancer, CMO, HKEX, Rutgers University, Learning, Biochemistry, Hospital, Mentorship, Oncology, Research, Hematology, IIC, Tufts Medical Center, Partnership, Pharmaceutical industry, NF-1, Molecular biology, Melanoma, Environment, Certification, Science, GSK, Patient, TMB, Faculty, Harvard Medical School, Pembrolizumab, Drug development, Merck, Massachusetts General Hospital, Autoimmunity, SAN, Dana–Farber Cancer Institute

Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical Development program.

Key Points: 
  • Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical Development program.
  • Dr. Nageatte Ibrahim has over 11 years of oncology industry drug development experience at Merck and GSK.
  • Dr. Ibrahim possesses a Pennsylvania Medical License and ABIM Certification in Medical Oncology.
  • "We are very excited to welcome Dr. Nageatte Ibrahim onboard as our Oncology CMO in Global Clinical Development," said Dr. Michael Yu, Founder, Chairman and CEO of Innovent.

TD Asset Management Inc. Launches Canadian and U.S. Target Maturity Bond ETFs

Retrieved on: 
Mardi, avril 9, 2024
Toronto-Dominion Bank, ETF, Trust, TMB, Toronto Stock Exchange, Insurance, Prospectus, TSX, Investment, Security (finance)

TORONTO, April 9, 2024 /CNW/ - Today, TD Asset Management Inc. ("TDAM") announced the addition of six new actively managed fixed income Exchange-Traded Funds ("TD ETFs"), the TD Target Maturity Bond ETFs ("TD TMB ETFs") to its comprehensive fixed income suite.

Key Points: 
  • TORONTO, April 9, 2024 /CNW/ - Today, TD Asset Management Inc. ("TDAM") announced the addition of six new actively managed fixed income Exchange-Traded Funds ("TD ETFs"), the TD Target Maturity Bond ETFs ("TD TMB ETFs") to its comprehensive fixed income suite.
  • This new suite of TD TMB ETFs has the benefits of diversification and professional management that comes with TDAM's Fixed Income Investment Team.
  • Each of the TD TMB ETFs seeks to provide regular income and preserve capital by investing primarily in a portfolio of investment-grade corporate bonds, with the TD Target Maturity Canadian Bond ETFs focusing on investment-grade Canadian corporate bonds denominated in Canadian dollars, and the TD Target Maturity U.S.
  • TD ETFs are managed by TD Asset Management Inc., a wholly-owned subsidiary of The Toronto-Dominion Bank.

Inocras to Present Enhancing Genomic Analysis in Cancer Diagnostics at the 2024 AACR Annual Meeting

Retrieved on: 
Vendredi, avril 5, 2024
Oncology, Health, Genetics, Other Health, Research, Science, Biotechnology, WGS, FF, Algorithm, TMB, Tissue, Cancer, AACR, Whole genome sequencing, HRD, Poster, Multimedia, Machine learning, Artifact, Therapy, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240405427133/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240405427133/en/
    Inocras presenting at the 2024 American Association for Cancer Research (AACR 2024) in San Diego, USA.
  • Our research findings presented at AACR 2024 will underscore the potential of machine learning in revolutionizing personalized cancer treatment strategies."
  • Inocras's participation in AACR 2024 showcases the company's relentless dedication to leveraging technological innovation to revolutionize cancer research and clinical practice.
  • For more information about Inocras and its groundbreaking research presented at AACR 2024, please visit Inocras.

Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics

Retrieved on: 
Mercredi, avril 3, 2024
Oncology, Health, Health Technology, Genetics, Other Science, Research, Science, Genomics, IHC, Methylation, Partnership, Laser, TMB, NGS, MSI, DNA, Biomarker, Cancer, Hydrofluoroolefin, Biology, Medicine, Imperial College London, AACR, Microsatellite instability, Neoplasm, Therapy, Agilent Technologies, Liquid biopsy, Machine learning, RNA-Seq, University of Oxford, CMO, Medical imaging

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .
  • Agilent Avida - Agilent Avida’s new cutting-edge target enrichment solutions enable simultaneous DNA and methylation profiling from a single sample.
  • Agilent SureSelect Cancer Custom panels - Agilent SureSelect Cancer Custom panels offer the ability to add new and emerging biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), to custom tumor genomic profiling assays.
  • AACR attendees can also explore multiple Agilent research posters and over 50 additional customer posters highlighting Agilent instruments and solutions.

Parks Associates Addresses Streaming Services and the Multifamily Market at Future of Video and Smart Spaces Virtual Series

Retrieved on: 
Mardi, mars 19, 2024
Sling TV, ROI, GM, Toll Brothers, JWP, Jukin Media, TMB, OTT, SVP, Internet, Research, Interview, Life, Streaming television, Trusted Media Brands, JW, Property technology, Future, CMO, CTV, Kwikset, FPT, Video game

DALLAS, March 19, 2024 /PRNewswire/ -- Parks Associates forecasts the US will have 129.6 million internet households in 2029, more than 92% of all households. These high-speed connections are the foundation for current and future services across multiple markets, including streaming video services and the multifamily market. The research firm will host Future of Video: Business of Streaming and Smart Spaces virtual sessions on March 21, addressing the transformation of multifamily and video distribution as a result of connectivity and technology advancements.

Key Points: 
  • These high-speed connections are the foundation for current and future services across multiple markets, including streaming video services and the multifamily market.
  • The research firm will host Future of Video: Business of Streaming and Smart Spaces virtual sessions on March 21, addressing the transformation of multifamily and video distribution as a result of connectivity and technology advancements.
  • "Access to high-speed internet is important in modern living – and connectivity is embedded in many everyday aspects of life at work and home," said Elizabeth Parks , President and CMO, Parks Associates.
  • Parks Associates and Future of Video sponsors, JWP (JW Player), Adeia, Bango, and FPT, invite the industry and press to join with this code: FOVVIRTUALVIP .

Caris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's Cancer

Retrieved on: 
Mercredi, mars 13, 2024
Diagnosis, PR, UCS, NCI, Ovarian cancer, Promise, OSCC, Survival, EEC, Exome sequencing, Glomus tumor, TMB, Patient, Neoplasm, NGS, Biomarker, Research, DNA, RNA, Cancer, AI, SGO, Carcinosarcoma, MD, Endometrial cancer, Medicine, Abstract, POA, Prognosis, Poster, ETS, Medical imaging

IRVING, Texas, March 13, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present three studies across multiple gynecological tumor types at the 2024 SGO Annual Meeting on Women's Cancer, March 16-18, 2024, in San Diego. The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene, to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene
    "We are proud to return and present an array of precision oncology research at this year's SGO Annual Meeting.
  • The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) criteria classify four molecular subtypes of endometrial tumors (ET).
  • Poster and abstract summaries highlighting the Caris research presented at SGO 2024 will be available onsite at Caris' booth (#601).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.